- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | Cannara Biotech Inc (2): Cannara increases credit facility to $80-million | 2 | Stockwatch | ||
| CANNARA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 01.09. | Cannara Biotech Inc (2): Cannara Biotech appoints Fozard CFO | 1 | Stockwatch | ||
| 01.09. | Nicholas Fozard wird neuer Finanzvorstand bei Cannara Biotech | 1 | Investing.com Deutsch | ||
| 01.09. | Cannara Biotech names Nicholas Fozard as chief financial officer | 2 | Investing.com | ||
| 13.08. | Cannara Biotech Inc (2): Cannara arranges automatic share purchase plan | 1 | Stockwatch | ||
| 22.07. | Cannara Biotech Inc (2): Cannara gets OK from TSX for NCIB | 1 | Stockwatch | ||
| 22.07. | Cannara Biotech Inc.: Cannara Announces Normal Course Issuer Bid | 2 | GlobeNewswire (USA) | ||
| 15.07. | Cannara Q3 2026 slides: revenue climbs 16% as cash flow drops | 2 | Investing.com | ||
| 15.07. | Cannara Biotech Reports Q3 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| 15.07. | Cannara Biotech Inc.: Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion | 371 | GlobeNewswire (Europe) | Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA1... ► Artikel lesen | |
| 15.07. | Cannara Biotech reports Q3 results | 3 | Seeking Alpha | ||
| 15.07. | Curaleaf Holdings Inc (2): Cannara Biotech, Curaleaf sign supply agreement | 2 | Stockwatch | ||
| 15.07. | Cannara Biotech Inc (2): Cannara Biotech, Curaleaf sign supply agreement | 2 | Stockwatch | ||
| 14.07. | Stocks in Play: Cannara Biotech Inc. | 1 | Baystreet.ca | ||
| 08.07. | Cannara Biotech Inc (2): Cannara Biotech to release Q3 results on July 15 | 1 | Stockwatch | ||
| 02.07. | Cannara Biotech Inc (2): Cannara obtains Canadian rights to Ampersand technology | 1 | Stockwatch | ||
| 02.07. | Cannara Biotech Inc.: Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand Live Rosin Infusion Technology | 881 | GlobeNewswire (Europe) | MONTREAL, July 02, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara", the "Company", "us" or "we") (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade... ► Artikel lesen | |
| 07.05. | Cannara Biotech Inc (2): Cannara Biotech closes Medican Organic acquisition | 1 | Stockwatch | ||
| 14.04. | Cannara Biotech GAAP EPS of $0.02, revenue of $27.1M | 1 | Seeking Alpha | ||
| 14.04. | Cannara Biotech Inc.: Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec | 407 | GlobeNewswire (Europe) | Delivered strong Q2 financial results: Generated $27.2 million in total net revenues, $11.6 million in gross profit before fair value adjustments or 43% of revenues, $6.0 million in adjusted EBITDA1... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,775 | +0,62 % | Novo Nordisk-Aktie: Neue Milliarden-Ziele - reicht das für die Wende? | Novo Nordisk will nach den Rückschlägen der vergangenen Monate wieder nach vorne schauen. Auf dem heutigen Kapitalmarkttag wurden große Ziele für die kommenden Jahre vorgestellt. Gleichzeitig gibt es... ► Artikel lesen | |
| AURORA CANNABIS | 3,556 | -1,00 % | Aurora Cannabis Inc.: Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure | NASDAQ | TSX: ACB
Aurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws.
Aurora intends to demonstrate... ► Artikel lesen | |
| CANOPY GROWTH | 0,820 | +0,61 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| STADA ARZNEIMITTEL | - | - | Biosimilars: Stada: Pembrolizumab aus China | ||
| TILRAY BRANDS | 3,555 | -2,07 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| INNOCAN PHARMA | 1,325 | +10,88 % | Innocan Pharma Corporation: Innocan Pharma Announces First Tranche Closing of Private Placement of Units | HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further... ► Artikel lesen | |
| CRONOS GROUP | 2,882 | -1,84 % | Cronos Group Inc.: Cronos Hosts 2026 Investor Day | ||
| SYNBIOTIC | 0,931 | +6,40 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| DIGICANN VENTURES | 0,005 | 0,00 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,956 | 0,00 % | Organigram Global Inc.: Organigram Global treibt die Integration der Sanity Group unter einer einheitlichen globalen Betriebsstruktur voran | Führung, operatives Geschäft und Marktentwicklung werden über eine globale Plattform aufeinander abgestimmt, die Kanada mit Deutschland und anderen wichtigen internationalen Märkten verbindet
Die... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,960 | +1,61 % | Green Thumb Industries Inc: Green Thumb to release Q3 2026 results Nov. 4 | ||
| SNDL | 1,210 | 0,00 % | Immortal Dragons: Sundial Initiative Advisor Boyang Wang Sponsors Nakauchi Lab's Work on "Bodyoids" | SINGAPORE, SG / ACCESS Newswire / July 30, 2026 / Boyang Wang, advisor to the Sundial Initiative and founder and CEO of the longevity fund Immortal Dragons, has sponsored the Nakauchi Lab, led by stem... ► Artikel lesen | |
| CRESCO LABS | 0,633 | -3,36 % | Cresco Labs Inc: Cresco to seek holder OK for three special resolutions | ||
| NOVERIS HEALTH SCIENCES | 0,050 | -13,16 % | Noveris Health Sciences Inc.: Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 3,232 | -3,00 % | Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trial Following FDA IND Clearance |
CANNARA BIOTECH INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANNARA BIOTECH INC finden Sie auf Wallstreet Online.